Your session is about to expire
← Back to Search
Fludarabine for Chronic Myelomonocytic Leukemia
Study Summary
This trial is testing a new immunotherapy for leukemia that uses T cells that have been genetically modified to target a protein found on the surface of leukemia cells.
- Chronic Myelomonocytic Leukemia
- Chronic Myelogenous Leukemia
- Biphenotypic Leukemia
- Acute Myeloid Leukemia
- Acute Leukemia
- Myelodysplastic Syndrome
- Minimal Residual Disease
- Leukemia
- Acute Lymphoblastic Leukemia
- Myelodysplastic Syndromes
- Acute Undifferentiated Leukemia
- Myelomonocytic Leukemia
- Undifferentiated Leukemia
- Blastic Plasmacytoid Dendritic Cell Neoplasm
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 30 Patients • NCT01877837Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the maximum participant count for this experiment?
"Affirmative. Clinicaltrials.gov information confirms that the trial, which was first uploaded on February 23rd 2018, is actively recruiting patients at a single site and searching for 24 volunteers overall."
Is the research endeavor currently admitting new participants?
"According to clinicaltrials.gov, this trial is open for enrollment and has been so since its initial posting on February 23rd 2018 with the most recent update occurring on September 7th 2022."
What goals is this clinical trial striving to achieve?
"This clinical trial will measure the efficacy of administering minor H antigen (HA-1) T cell receptor (TCR) CD8+ and CD4+ T cells over a given time frame. Secondary objectives include assessing the presence, proportion, and persistence of HA-1 TCRs in bone marrow via tetramer or qPCR testing; measuring how long these receptors stay in peripheral blood; as well as determining what percentage of participants develop symptoms or signs related to graft versus host disease through standard GVHD grading criteria."
Has the Food and Drug Administration green-lit Fludarabine for public use?
"Fludarabine is still in the early stages of development, so its safety was provisionally given a score of 1. Currently, there is limited data on both efficacy and safety for this medication."
Are there any other precedents of Fludarabine being used in medical research?
"As of the present, 369 trials are underway investigating Fludarabine. Of these active studies, 22 have progressed to Phase 3. Boston Massachusetts holds the most concentration of such clinical research though there are 3764 sites across America conducting related investigations."
Share this study with friends
Copy Link
Messenger